Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@article{Andr2004OxaliplatinFA,
  title={Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.},
  author={Thierry Andr{\'e} and Corrado Boni and Lamia Mounedji-Boudiaf and Matilde Navarro and Josep Tabernero and Tamas Hickish and Clare Topham and Marta Zaninelli and Philip R. Clingan and John A Bridgewater and Isabelle Tabah-Fisch and Aimery de Gramont},
  journal={The New England journal of medicine},
  year={2004},
  volume={350 23},
  pages={
          2343-51
        }
}
BACKGROUND The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was… 

Figures and Tables from this paper

Oxaliplatin: in operable colorectal cancer.
TLDR
Results from several phase I/II studies suggest that the addition of oxaliplatin to preoperative radiochemotherapy may be of benefit in patients with locally advanced lower rectal cancer in terms of disease downstaging and sphincter preservation.
THE EFFICACY AND TOXICITY OF OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN AS ADJUVANT TREATMENT IN PATIENTS WITH COLON CANCER
TLDR
It is now acceptable to consider combination chemotherapy with FolFox -4 as adjuvant treatment for high risk colon cancer patients after curative surgery at Kasr El Ainy center of Radiation Oncology and nuclear medicine.
Adjuvant Systemic Chemotherapy with 5-Fluorouracil and Leucovorin in Colon Cancer: A Monoinstitutional Institutional Experience
TLDR
The treatment was generally well tolerated and there was no therapy related death and no clinical immonotoxicological effects was observed also in elderly patients, and the survival observed in the retrospective study reflects that reported in the chemotherapy arm of randomized clinical trials.
Capecitabine as adjuvant treatment for stage III colon cancer.
TLDR
Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
TLDR
The addition of oxaliplatin to capecitabine improves DFS in patients with stage III colon cancer, and XELOX is an additional adjuvant treatment option for these patients.
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
TLDR
The addition of CPT-11 to weekly bolus FU plus LV did not result in improvement in DFS or OS in stage III disease, but did increase both lethal and nonlethal toxicity.
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
TLDR
The completion rate of the first four cycles of FOLFOX4 was as high as expected with manageable toxicity, although fatal pneumonitis developed in one case.
Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
TLDR
In this population of Korean colon cancer patients, adjuvant chemotherapy showed superior survival to curative surgery alone and significantly reduced the risk of death.
ADJUVANT INFUSIONAL FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT OXALIPLATIN IN TREATMENT OF STAGE II AND III COLON CANCER
TLDR
Patients with stage III and high-risk stage II colon cancer obtain benefit from the addition of oxaliplatin to infusional fluorouracil plus leucovorin as adjuvant therapy.
Adjuvant chemotherapy in colon cancer: ageism or appropriate care?
  • J. Hubbard, A. Jatoi
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Examining 2,560 patients from the IntelliDose (IntrinsiQ, Burlington, MA) ordering system during the past six and a half years, these investigators observed that such clinical trial evidence does appear to modify clinical practice and has this designation of the standard of care led to the routine use of oxaliplatin-based chemotherapy in the appropriate adjuvant settings.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
TLDR
Results indicate that intensive-course 5FU plus low-dose leucovorin is effective in preventing tumor relapse and improving survival in patients with high-risk colon cancer.
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.
  • C. Erlichman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
This data set does not support the routine use of FU + LV in all patients with B2 Colon cancer, and studies in B2 colon cancer designed with a no-treatment control arm should be considered appropriate.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
TLDR
The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
  • R. Goldberg, D. Sargent, S. Alberts
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe and should be considered as a standard therapy for patients with advanced colorectal cancer.
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
TLDR
The data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-fu plus leucovorin plus lev amisole is effective.
Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
  • A. Zaniboni
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
The results of these randomized trials support the use of high-dose leucovorin/5-FU as adjuvant therapy for colorectal cancer, with significant improvements in both DFS and overall survival observed over surgery alone (control).
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
TLDR
Adjuvant therapy with levamisole and fluorouracil should be standard treatment for Stage C colon carcinoma, and this approach should be readily adaptable to conventional medical practice.
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
TLDR
Treating patients with Dukes' stage B and C carcinoma of the colon with leucovorin-modulated fluorouracil as adjuvant therapy significantly prolongs disease-free survival and results in a significant benefit relative to overall survival.
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
TLDR
By chronomodulating 5-FU-LV, the authors were able to add l-OHP without compromising dose-intensities and significantly improved the antitumor efficacy of this regimen.
...
...